undamentalytics Newsletter
Sign in

Renovorx, Inc. (RNXT) stock

Add to watchlist

Add holding +

NASDAQ: RNXT Nasdaq Health Care Equipment Next results ~November 5, 2026

Renovorx, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Renovorx, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: limited reported history: available models are shown without a Buy/Hold/Sell rating. We'll show the comparison once resolved.

Renovorx, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders4 buying, 0 selling13 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds11 adding, 12 cuttingOf 2 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 33% in the quarter to 2026-06-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Loss-making. Operating margin is -685.2%: costs exceed revenue.
  • Burning cash. Free cash flow was -604.1% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 77.0% of revenue: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 34.4% in a year.
  • High sales multiple. The shares trade at 25 times revenue while operating margins remain thin.
  • Volatile shares. Over the past year the shares showed annualised volatility of 85% and a beta of 1.5 against the S&P 500.

Latest results: FY2026 Q2

Filed August 13, 2026
Earnings per share
-$0.05 against an average estimate of -$0.07: beat by 33.3%
Revenue
$1m, up 115.4% on a year earlier
Next report
November 5, 2026; average EPS estimate -$0.05

Renovorx's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-5.3%
  • 1 week-3.8%
  • 1 month-20.3%
  • This year+50.0%
  • 1 year+13.5%
  • 5 years-76.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$2M
Operating margin
-685.2%
Net margin
-621.7%
EPS (TTM, diluted)
$-0.31

Growth

Share count change
+34.4%

Cash

Free cash flow (TTM)
-$11.9M
FCF margin
-604.1%
Stock pay % of revenue
77.0%

Earnings

Last results
May 14, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Renovorx, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Renovorx, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.8%: the 10-year Treasury yield (4.9%) plus a beta of 1.08 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.0 ~$0.1–$0.2 Left out: out of range vs price (0.03x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Renovorx, Inc. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20242025Now
Share price$1.29$0.84$1.26
Market value$29m$30m$50m
+ Net debt (− = net cash)−$7m−$7m−$9m
Enterprise value$22m$23m$41m
Multiples
Price / sales n/m26.4x25.3x
Price / earnings ———
Price / free cash flow ———
EV / EBITDA ———

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $1m and EPS of −$0.05 (range −$0.07 to −$0.03) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.27 +16% $4m +245%
Next −$0.12 +56% $11m +195%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −18.2% on 90 days ago. In the last 30 days, 1 analyst raised Renovorx, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Renovorx, Inc., last 90 days
−$0.40 −$0.30 −$0.20 −$0.10 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.33 Current fiscal year, 60 days ago: −$0.31 Current fiscal year, 30 days ago: −$0.31 Current fiscal year, 7 days ago: −$0.29 Current fiscal year, Now: −$0.27 −$0.27 Next fiscal year, 90 days ago: −$0.13 Next fiscal year, 60 days ago: −$0.15 Next fiscal year, 30 days ago: −$0.15 Next fiscal year, 7 days ago: −$0.15 Next fiscal year, Now: −$0.12 −$0.12

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.33−$0.13
60 days ago −$0.31−$0.15
30 days ago −$0.31−$0.15
7 days ago −$0.29−$0.15
Now −$0.27−$0.12

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.07 −$0.05 +33.3%
Mar 2026 −$0.08 −$0.08 −4.3%
Dec 2025 −$0.08 −$0.08 0.0%
Sept 2025 −$0.08 −$0.08 0.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

4 analysts, Oct 2026
Buy4100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202644
  2. Sep 202644

Counts of recommendations published by analysts covering Renovorx, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
2.0%
of tradable shares
Days to cover
1.47
at average volume
Short interest, 1 month
+28%
to October 15, 2026
Held by institutions
21%
of shares
Held by insiders
3.6%
of shares
Employees
17
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20222023202420252026 to date
Return
RNXT−51%−3%−44%−35%+50%
Industry peers (median)−37%−9%−19%−16%−15%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
RNXT50%33%42%25%46%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
RNXT−69%−89%−61%−52%−56%
S&P 500−25%−10%−8%−19%−9%

Worst fall since August 26, 2021: 96% from August 30, 2021 to November 17, 2023. Getting back needed a 2570% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.73 – $2.52
From 52-week high
−50.0%
vs 50-day average
−19.2%
vs 200-day average
+14.1%
Volatility (1 year)
85%
Beta vs S&P 500
1.51

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±10.0%
After a week
5 up, 7 down
typical move ±14.7%
After a month
5 up, 7 down
typical move ±12.1%
Results releasedNext dayS&P 500 next day5 days21 days
May 14, 2026 −3.4% −0.4% +3.9% +4.4%
March 30, 2026 −10.6% +2.6% −20.4% −26.5%
November 13, 2025 −25.0% −1.7% −22.2% −6.0%
August 14, 2025 −21.6% −0.2% −26.8% +4.1%
May 15, 2025 +12.4% +1.1% +17.1% +24.8%
April 1, 2025 +1.0% +0.9% −19.2% 0.0%
November 14, 2024 0.0% −1.9% +11.0% +14.7%
November 14, 2023 −29.1% +2.2% −40.9% −8.4%
August 17, 2023 +0.6% −0.7% +0.6% −12.9%
May 15, 2023 +9.9% −0.3% +1.0% −0.5%
March 2, 2023 +2.0% +2.4% −11.6% −31.7%
November 14, 2022 +4.3% 0.0% −2.1% +11.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 1 2
Gross profit 0 1 2
EBITDA −11 −11 −13
Operating income −11 −13 −14
Net income −9 −11 −12
Diluted EPS −$0.40 −$0.32 −$0.31
Growth (year on year)
Revenue — +>999% —
Margins
Gross margin 100.0% 70.9% 84.4%
EBITDA margin <−999% −935.9% −634.3%
Operating margin <−999% <−999% −685.2%
Net margin <−999% −994.5% −621.7%
Free-cash-flow margin <−999% −977.3% −604.1%
Cash flow
Cash from operations −9 −11 −12
Capital spending 0 0 0
Free cash flow −9 −11 −12
Stock-based pay 1 1 2
Free cash flow after stock pay −10 −12 −13
Balance sheet
Cash 7 7 9
Total debt 0 0 0
Net debt (negative = net cash) −7 −7 −9
Diluted shares 22m 35m 40m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $11m
Short-term assets $11mLonger-term assets $1m
What it owes, and who funded it · $11m
Short-term liabilities $2mLonger-term liabilities $1mShareholders' equity $9m
  • Short-term assets cover short-term liabilities $11m of assets due within a year against $2m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $11m short-term assets against $609,000 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Renovorx, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+34.4%
year over year
R&D spending
284.1%
of revenue
Sales & admin spending
485.5%
of revenue
Days sales outstanding
89 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated RNXT ICU FEMY IMDX VNRX PLSE Median
Revenue, last 12 months $2m $2m $2m $2m $2m $1m $95m
Revenue growth, last 12 months — 123.6% 21.9% −60.8% 86.3% 100.0% 9.2%
Revenue growth, 3-year average — — 24.3% 14.9% 68.0% — 13.5%
Revenue growth, latest quarter 115.4% 82.0% −18.9% −53.9% −2.0% 100.0% 10.5%
Gross margin 84.4% 92.6% 60.9% 48.3% — 0.3% 61.3%
Operating margin −685.2% −816.6% −763.9% <−999% −790.2% <−999% −8.7%
Operating margin, 3-year average — — <−999% <−999% <−999% >999% −17.9%
Net margin −621.7% −795.5% −511.8% <−999% <−999% <−999% −12.1%
Cash from operations / revenue −600.5% −799.4% −767.6% <−999% −795.9% <−999% −2.1%
Free-cash-flow margin −604.1% — −786.0% <−999% −796.7% <−999% −4.0%
Free-cash-flow margin, 3-year average — — <−999% <−999% <−999% >999% −7.0%
Stock pay / revenue 77.0% 20.5% 26.2% 150.8% 38.2% >999% 6.3%
Change in share count 34.4% — — 16.8% 16.3% 7.4% 4.0%

Median of all 135 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling
Reported value
$9M
Institutions reporting
28
Shares held vs prior quarter
▲ 7.4%
Positions opened / closed
3 / 6

Top buyers and sellers, Q2 2026: 11 institutions bought and 12 sold ; the biggest buyer was Aigh Capital Management LLC (+699K shares) and the biggest seller Citadel Advisors LLC (−99K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Aigh Capital Management LLC $4.3M 4.4M 48.0% ▲ 18.9%
Bleichroeder LP $1.6M 1.7M 18.1% 0.0%
Vanguard Capital Management LLC $1.4M 1.4M 15.7% ▼ 0.2%
Geode Capital Management, LLC $415,687 424K 4.6% ▲ 11.1%
Wealthspire Advisors, LLC $247,475 253K 2.7% 0.0%
Vanguard Fiduciary Trust Co $235,523 240K 2.6% ▲ 52.2%
Citadel Advisors LLC $130,925 134K 1.5% ▼ 42.6%
Northern Trust Corp $83,503 85K 0.9% ▲ 102.1%
Chicago Partners Investment Group LLC $78,918 92K 0.9% 0.0%
Northwestern Mutual Wealth Management Co $73,104 75K 0.8% ▼ 25.0%
Caprock Group, LLC $62,661 64K 0.7% 0.0%
Jane Street Group, LLC $45,471 46K 0.5% ▲ 92.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Renovorx, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $84,494 13 trades by 4 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $84,494 net buying
Insider Date Trade Shares Price Value
Voll Mark Chief Financial Officer May 19, 2026 Buy 25,000 $0.79 $19,750
Voll Mark Chief Financial Officer March 20, 2026 Buy 97,200 — $0
Bagai Shaun Chief Executive Officer March 20, 2026 Buy 24,300 — $0
Marton Laurence Director March 20, 2026 Buy 9,720 — $0
Agah Ramtin Chief Medical Officer January 21, 2026 Buy 10,000 $1.00 $10,000
Agah Ramtin Chief Medical Officer December 31, 2025 Buy 9,795 $0.86 $8,424
Agah Ramtin Chief Medical Officer December 30, 2025 Buy 205 $0.83 $170
Bagai Shaun Chief Executive Officer December 18, 2025 Buy 5,000 $0.90 $4,500
Bagai Shaun Chief Executive Officer December 17, 2025 Buy 5,000 $0.85 $4,250
Agah Ramtin Chief Medical Officer December 16, 2025 Buy 12,000 $0.85 $10,200
Agah Ramtin Chief Medical Officer December 5, 2025 Buy 10,000 $0.96 $9,600
Agah Ramtin Chief Medical Officer November 24, 2025 Buy 12,000 $0.80 $9,600

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around August 13, 2026 estimated from the company's past filing pattern, not announced

  • May 14, 2026
  • March 30, 2026
  • November 13, 2025
  • August 14, 2025
  • May 15, 2025
  • April 1, 2025

Recent SEC filings

Data status

When each part of this page on Renovorx, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Renovorx, Inc. in brief

What does Renovorx, Inc. do?
Renovorx, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Renovorx, Inc.'s stock ticker?
Renovorx, Inc. trades under the ticker RNXT on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Renovorx, Inc.'s free cash flow?
Renovorx, Inc.'s free-cash-flow margin is -604.1% of revenue over the trailing twelve months.
Who are Renovorx, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Aigh Capital Management LLC, Bleichroeder LP and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Renovorx, Inc.'s market cap?
On November 2, 2026, Renovorx, Inc.'s market capitalisation was about $50M and net debt of -$9.5M. Market figures come from third-party market data and may be delayed.
Who are Renovorx, Inc.'s competitors?
In our Health Care Equipment peer group, the companies closest to Renovorx, Inc. are Seastar Medical Holding Corp, Femasys Inc, Insight Molecular Diagnostics Inc., Volitionrx LTD and Pulse Biosciences, Inc. The side-by-side comparison below sets their revenue, margins and growth against Renovorx, Inc.'s.
Are insiders buying or selling Renovorx, Inc. stock?
Over the last 12 months, Renovorx, Inc.'s directors and officers reported 13 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Renovorx, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Renovorx, Inc. announces its own schedule.